Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
June 13, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the...
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
May 03, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
April 25, 2022 07:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
April 21, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 01, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
Received FDA approval for CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the first and only FDA-approved treatment for depressive episodes associated with...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
February 22, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 07, 2022 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...